Cooperative Agreement UG3DA062511
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$2.9M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $541,080 to The Trustees of Columbia University in the City of New York to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine versus sublingual buprenorphine/naloxone in treating opioid use disorder (OUD) among individuals who use high-potency synthetic opioids. The key objectives are to compare abstinence and...
This $201,960 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to address gaps in the understanding and utilization of extended-release buprenorphine (XR) for the treatment of opioid use disorder (OUD). The 2-year grant, effective July 1, 2025, will enable the principal investigator at the University of Utah to: 1) assess current demographic differences in real-world XR treatment for OUD...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $267,000 Project Grant (R21DA058120) to The Children's Hospital Corporation (Boston Children's Hospital) to develop depot formulations for on-demand, tamper- and diversion-proof delivery of opioids. The goal is to create injectable polymer-based depot formulations that are covalently bonded to opioids via photolabile linkers, which would make the formulations resistant to...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...
The National Institute on Drug Abuse (NIDA) awarded Rebel Medicine Inc. a $591,842 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an extended-duration injectable local anesthetic formulation as an alternative to opioid-based pain medications. The project aims to demonstrate the safety and efficacy of a proprietary lipophilic bupivacaine oleogel formulation that can provide up to 7 days of sustained pain relief from a single injection, mitigating the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for treating opioid use disorder (OUD). The $398,137 award to Boston Interactome LLC, effective May 1, 2025 through April 30, 2026, will fund research to identify functional modulators of the G9A epigenetic protein complex that regulates DFosB expression under chronic opioid exposure. The goal...
This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,710,576.00 to Mebias Discovery Inc. to develop a new chemical entity, MEB-1170, as a maintenance medication for the treatment of opioid use disorder (OUD). The project aims to complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 in reducing fentanyl self-administration and its safety...
This federal Project Grant award of $4,665,000 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The award will fund the development and testing of a novel "Community-Based Opioid Treatment (CBOT)" implementation strategy to deliver buprenorphine for opioid use disorder treatment and HIV prevention/care services to people who use opioids. The project will involve two parts -...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...